Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Journal of Thoracic DiseaseOpen Access

Enhancement of anti-programmed cell death protein-1 immunotherapy in non-small cell lung cancer using arginine and citrulline supplementation

View Full Paper
Ask AI
Bookmark
Share

Authors

NMNaoki MiyamotoMYMitsuteru YoshidaSTShin‐ichi Tsukumo

Discussion

Loading...

Member takes

Implication

Analysis reveals that citrulline enhances anti-PD-1 immunotherapy outcomes, suggesting a new approach in lung cancer treatment.

Key Points

  • Citrulline supplementation significantly decreases tumor volumes in lung cancer models when combined with anti-PD-1 therapy.
  • The combination therapy improved progression-free survival rates compared to control, illustrating enhanced efficacy.
  • Mice treated with arginine and citrulline showed higher levels of CD8+ lymphocytes, proving improved immune response.
  • This study highlights the potential of amino acid supplementation in cancer immunotherapy strategies.

Cite This Study

Miyamoto et al. (2025) studied this question.

synapsesocial.com/papers/68c23e02b210217d64790622https://doi.org/10.21037/jtd-2024-2109
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Enhanced cancer immunotherapy via synergistic action of NO-Donor nanoparticles (Nano ARG ) and PD-1 antibody2025 · 2 citations
  2. 2Treatment of refractory non-small cell lung cancer with combined infusion of modified CIK cells and PD1 antibody: safety and efficacy2025 · 3 citations
  3. 3Synergistic Effect of Anti-PD-L1 Treatment and CD8+ T-Cell Activating Nanotherapy in Pancreatic Ductal Adenocarcinoma Evaluated via 3D Mathematical Modeling2025 · 1 citations
  4. 4PD-1 and PDL-1 Immune Checkpoint Inhibitors: Emerging Hope for the Future of Lung Cancer Immunotherapy2025
  5. 5Arginine deprivation activates immunogenic cell death and enhances anti-tumor immunity in diffuse large B-cell lymphoma2025